文献速递神经肿瘤

分子定义的低级别胶质瘤中手术的影响:一项整合临床、影像与分子分析的研究

The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.
PubMed 文献 · Neuro Oncol · 2018-01-01

该研究纳入228例自2003年起接受手术的幕上低级别胶质瘤成人患者,用半自动软件在T2加权像上评估术前和术后肿瘤体积,并用靶向二代测序按当前WHO分类对样本进行分子分型。中位随访5.79年,多变量分析显示术后体积每增加1 cm³与总生存期相关(HR 1.01,95%CI 1.002-1.02,P=0.016),在IDH突变型星形细胞瘤中即使很小的术后残留体积(0.1-5.0 cm³)也已对总生存期产生负面影响。

要点

  • 术后体积每增加1 cm³,总生存期HR为1.01(95%CI 1.002-1.02,P=0.016)。
  • IDH突变型星形细胞瘤中,术后残留体积0.1-5.0 cm³已对总生存期产生负面影响。
  • 作者支持将最大程度切除作为分子定义低级别胶质瘤的一线治疗。

核心结论

  • 研究数据支持将最大程度切除作为分子定义低级别胶质瘤的一线治疗。
  • 在IDH突变型星形细胞瘤中,即使很小的术后残留体积也对总生存期有负面影响,作者认为若安全可行,该亚型可考虑二次手术以清除小残留。

研究设计与样本

  • 纳入228例自2003年起接受手术的幕上低级别胶质瘤成人患者。
  • 术前和术后肿瘤体积用半自动软件在T2加权像上评估。
  • 采用靶向二代测序按当前WHO分类对样本进行分子分型。
  • 使用Cox比例风险模型评估校正分子分型后术后体积对总生存期的影响。

主要发现

  • 中位随访时间为5.79年。
  • 39例(17.1%)组织病理学分类的胶质瘤在分子分析后亚型被修正。
  • 35例(15.4%)实现完全切除,54例(23.7%)仅残留小体积(0.1-5.0 cm³)。
  • 多变量分析中,术后体积与总生存期相关,体积每增加1 cm³的HR为1.01(95%CI 1.002-1.02;P=0.016)。
  • 术后体积的影响在IDH突变型星形细胞瘤患者中尤其明显,即使很小的术后体积(0.1-5.0 cm³)也已对总生存期产生负面影响。

临床怎么用

  • 作者支持将最大程度切除作为分子定义低级别胶质瘤的一线治疗。
  • 作者认为在IDH突变型星形细胞瘤中,若安全可行,可考虑二次手术以清除小残留。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extensive resections in low-grade glioma (LGG) are associated with improved overall survival (OS). However, World Health Organization (WHO) classification of gliomas has been completely revised and is now predominantly based on molecular criteria. This requires reevaluation of the impact of surgery in molecularly defined LGG subtypes. METHODS: We included 228 adults who underwent surgery since 2003 for a supratentorial LGG. Pre- and postoperative tumor volumes were assessed with semiautomatic software on T2-weighted images. Targeted next-generation sequencing was used to classify samples according to current WHO classification. Impact of postoperative volume on OS, corrected for molecular profile, was assessed using a Cox proportional hazards model. RESULTS: Median follow-up was 5.79 years. In 39 (17.1%) histopathologically classified gliomas, the subtype was revised after molecular analysis. Complete resection was achieved in 35 patients (15.4%), and in 54 patients (23.7%) only small residue (0.1-5.0 cm3) remained. In multivariable analysis, postoperative volume was associated with OS, with a hazard ratio of 1.01 (95% CI: 1.002-1.02; P = 0.016) per cm3 increase in volume. The impact of postoperative volume was particularly strong in isocitrate dehydrogenase (IDH) mutated astrocytoma patients, where even very small postoperative volumes (0.1-5.0 cm) already negatively affected OS. CONCLUSION: Our data provide the necessary reevaluation of the impact of surgery in molecularly defined LGG and support maximal resection as first-line treatment for molecularly defined LGG. Importantly, in IDH mutated astrocytoma, even small postoperative volumes have negative impact on OS, which argues for a second-look operation in this subtype to remove minor residues if safely possible.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Wijnenga MMJ, French PJ, Dubbink HJ, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2018. PMID: 29016833. doi:10.1093/neuonc/nox176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。